Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Inclusion Criteria: * Have completed the qualifying DM-230 trial * If females of child-bearing potential, subjects must be using adequate contraception * Provide written informed consent * Be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures * Be greater than 80% compliant in study medication use during the last three visits for DM-230 Exclusion Criteria: * Subjects who have developed one or more morbidities during the DM-230 trial that would pose a safety concern